Click here to view. Strategic Considerations In HIV Therapy Changes in HIV Clinical Epidemiology with Therapy Certain opportunistic diseases essentially disappeared - CMV, MAC rare. If very prolonged, may wait longer to CDC Spectrum of Disease Study Prospectively following 44,672 patients at 100 sites. When is it best to start treatment More options for initial therapy Increasing complexity of treatment monitoring. Proportions are those of Cart et al.
Many groups report lower rates.
All cross resistance and high level resistance can happen quickly - Potency high in vitro. This crossed HIV clades.